Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
4,927,548

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $73.77 -0.01 (-0.01%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

    David Bartosiak headshot

    Five Major Myths about Options Trading

    These are the five biggest myths about options trading

      Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

      Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

        Arpita Dutt headshot

        Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

        Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

          Gilead (GILD) Announces Data on Combination Therapy for HIV

          Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

            The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

            The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

              Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

              The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

                Arpita Dutt headshot

                Forget Gilead, Buy These 5 Biotech Stocks Instead

                With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                  Sweta Killa headshot

                  Biotech ETFs Powered by Q4 Earnings

                  Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

                    Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                    Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                      Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                        Tracey Ryniec headshot

                        Healthcare Stocks: The Buying Opportunity of the Year?

                        Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.

                          Madeleine Johnson headshot

                          Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance

                          Gilead Sciences Inc. (GILD) just released its fourth quarter fiscal 2016 financial results, posting earnings, before non-recurring items, of $2.64 cents per share and revenues of $7.3 billion

                            Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                            Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                              Arpita Dutt headshot

                              Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                              2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

                                There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.

                                  Gilead (GILD) HCV Therapy Application Validated in Europe

                                  Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                                    Is Gilead Sciences (GILD) a Great Stock for Value Investors?

                                    Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.

                                      The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

                                      The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

                                        4 Top Biotech Mutual Funds for 2017

                                        Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

                                          Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?

                                          Investors in Gilead Sciences Inc. (GILD) need to pay close attention to the stock based on moves in the options market lately.

                                            Gilead (GILD) HBV Drug Vemlidy Receives European Approval

                                            Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.

                                              Madeleine Johnson headshot

                                              Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment

                                              After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker

                                                  Sheraz Mian headshot

                                                  Top Research Reports for Pepsi, UPS & Gilead Sciences

                                                  Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Pepsi (PEP) and United Parcel Services (UPS).